In a biotechnology sector crowded with early-stage science projects and cash-burning platforms, Cadrenal Therapeutics (NASDAQ: $CVKD ) stands out as a rare anomaly. The company is advancing three distinct anticoagulation programs targeting high-risk patient populations where standard therapies are fundamentally broken. Its lead program, tecarfarin, is being developed for patients with left ventricular assist devices, or LVADs, in collaboration  with Abbott Laboratories (NYSE: